Haemophagocytic syndrome in an adult suffering from pyrexia of unknown origin: an uncommon presentation of tuberculosis: a case report
© The Author(s) 2017
Received: 2 August 2016
Accepted: 16 February 2017
Published: 27 February 2017
Tuberculosis is common, can involve various organs of the body and may have diverse presentations. Haemophagocytic syndrome is one of the rare presentations of tuberculosis carrying a very high mortality. Early detection and institution of anti-tuberculosis medications can be life-saving.
A 23-year-old Bengali man presented with prolonged fever, weight loss, hepatosplenomegaly, pancytopenia and altered liver function. He had high erythrocyte sedimentation rate, positive tuberculin test, granuloma in liver biopsy, and haemophagocytosis was evidenced by histopathological examination of bone marrow. He recovered with anti-tuberculosis therapy.
This case demonstrates that consideration of tuberculosis as an underlying cause of haemophagocytic syndrome could be rewarding and life-saving in this rapidly fatal condition.
KeywordsCase report Haemophagocytic syndrome Pyrexia of unknown origin Tuberculosis
Haemophagocytic syndrome (HPS) or haemophagocytic lymphangiohistiocytosis (HLH) is an uncommon disorder that may present with fever, lymphadenopathy and hepatosplenomegaly. Overactive macrophages phagocytose erythrocytes, leucocytes, platelets and their precursors in bone marrow and reticuloendothelial system. This syndrome can be primary or secondary. Primary HPS is a genetic disorder, occurs in younger age group. Secondary HPS may be triggered by viral infections like Epstein–Barr virus , but bacterial infections like tuberculosis (TB) is not uncommon [2–6]. Mortality ranges from 41 to 50% and in secondary HPS, delay in diagnosis increases mortality [7, 8]. Therefore, early recognition of the infective agent and treatment of the cause might be life-saving. We report this case to highlight TB as a cause of HPS in an adult patient and resolution of the disease with anti-TB treatment.
A 23-year-old Bengali man presented with two-month history of intermittent fever, oral ulcer, anorexia and 9-kg weight loss. He gave history of several episodes of vomiting over five days before hospitalization. He had no other significant history of note, except frequent visit to kala-azar endemic area (Tangail) and sex with commercial sex worker two years back. He denied any history of contact with known TB cases. For his problems he consulted several physicians, underwent various investigations, took several courses of broad spectrum antibiotics and one course of anti-malarial drug without any benefit. His pre-admission investigation reports were insignificant except raised alanine aminotransferase (ALT) (142 U/L) and ultrasonographic evidence of hepato-splenomegaly.
The patient was very ill [World Health Organization (WHO) performance status—Grade 3] and wasted with a body mass index (BMI) of 16.7 kg/m2, febrile (temp of 102 °F), pulse 112/min, blood pressure 130/80 mm Hg. He had an oral ulcer (1 cm × 1 cm) on the inner side of left cheek with regular margin and whitish surface without any local lymphadenopathy. He had 7-cm smooth-surfaced, firm, tender hepatomegaly and 3-cm splenomegaly without ascites. Other examination findings including chest, precordium and ocular fundi were normal.
Primary HPS occurs in young patients and usually associated with genetic disorders [9, 10]. Secondary HPS affects people of any age. The causes may be variable ranging from infections through autoimmune disorders to malignancy . Overall 3% of all HPS cases are associated with TB  and Tseng et al.  found that one-fourth of infection associated HPS among Taiwanese were due to Mycobacterium tuberculosis.
fever: peak temperature >38.5 °C for 7 or more days
splenomegaly: spleen palpated >3 cm below the left costal margin
cytopenia involving two or more cell lines: haemoglobin <9.0 g/dL, or platelet <100,000/µL, or absolute neutrophil count <1000/µL
hypertryglyceridaemia or hypofibrinogenaemia: fasting triglycerides >2.0 mmol/L, or more than 3 standard deviations (SD) above the normal value for age, or fibrinogen <1.5 g/L, or more than 3 SD below the normal value for age
haemophagocytosis: demonstrated in bone marrow, spleen, or lymph node; no evidence for malignancy
low or absent natural killer cell activity
serum ferritin level >500 µg/L (although >3000 µg/L is a more realistic cut off to exclude infections and
soluble CD25 (sIL-2 receptor) >2400 U/mL (note age-related norms).
Our patient had seven out of these nine criteria. Our center does not have the capacity to test for natural killer cell activity and soluble CD25.
Haemophagocytosis can be demonstrated among biopsy samples from bone marrow, liver or spleen, and bone marrow is an excellent sample for exhibiting haemophagicytosis associated with TB [2–4, 13]. As TB-associated HPS is rare, patients have been treated by different approaches. Brastianos et al.  in a review of 36 such cases found that anti-TB therapy alone showed better survival than combination of anti-TB drugs and various immunomodulatory therapies. In such cases, delay in diagnosis was found to be the most important factor for poor outcome . Our patient responded well to anti-TB treatment, prednisolone was administered only in initial periods.
It should be mentioned that being a high TB-burden country, in our clinical practice we encounter many cases of disseminated TB even in immunocomtetent individuals. Delay in establishing an aetiological diagnosis or haematogenous spread may be contributory in this particular case for such an advanced presentation.
Although associated with multiple conditions, TB should always be considered as cause of HPS in countries like Bangladesh where TB is endemic. An early diagnosis and treatment with appropriate anti-TB drugs is life-saving.
World Health Organization
body mass index
hepatitis B virus surface antigen
hepatitis C virus
veneral disease research laboratory
treponema pellidum haemaglutinine assay
human immunodeficiency virus
WMMH has managed the patient, done literature review, manuscript preparation and final approval of the draft. MERS has participated in management of the patient, data collection, literature search and drafting the manuscript. MAR has done literature search, editing the draft and final approval of the draft. PM has done literature review and drafting the case report. TS has done literature search, had critical intellectual contribution to the draft and final approval of the manuscript. JAH was the key microbiologist, had taken part in decision making in treating the patient and editing the draft. All authors read and approved the final manuscript.
The authors express their acknowledgement to Dr. Mohsin Kabir, Junior Consultant, Department of Gastro-Intestinal, Hepatobiliary and Pancreatic Diseases, BIRDEM General Hospital for his co-operation in doing liver biopsy, Professor Dr. Md. Sirajul Islam, Professor of Haematology, BIRDEM General Hospital, for his co-operation in doing and reporting bone marrow biopsy and Dr. Md. Delwar Hossain, Associate Professor, Department of Internal Medicine and Pulmonology, BIRDEM General Hospital and Professor Khwaja Nazim Uddin, Professor of Medicine of BIRDEM General Hospital for their co-operation in managing this patient.
The authors declare that they have no competing interests.
Consent to publish
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Janka GE. Haemophagocytic syndromes. Blood Rev. 2007;21(5):245–53.View ArticlePubMedGoogle Scholar
- Naha K, Dasari S, Vivek G, Prabhu M. Disseminated tuberculosis presenting with secondary haemophagocytic lymphangiohistiocytosis and Poncet’s disease in an immunocompetent individual. BMJ Case Rep. 2013. doi:10.1136/bcr-2012-008265.Google Scholar
- Cherif E, Feki NB, Hassine LB, Khalfallah N. Haemophagocytic syndrome with disseminated intravascular coagulation associated with tuberculosis. BMJ Case Rep. 2013. doi:10.1136/bcr-2013-008743.Google Scholar
- Li J, Yu S, Wang M, Chen HB, Wang W. A case of hemophagocytic lymphohistiocytosis syndrome caused by severe tuberculosis and literature review. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35(10):766–9.PubMedGoogle Scholar
- Aggarwal P, Kumar G, Dev N, Kumari P. Haemophagocyticlymphangiohistiocytosis: a cause of rare but fatal outcome in tuberculosis. BMJ Case Rep. 2012. doi:10.1136/bcr-2012-006982.Google Scholar
- Manoj EM, Srigrisha R, Raghunathan MK. Hepatic tuberculosis presenting with extreme hyperferritinaemia masquerading as adult-onset Still’s disease: a case report. J Med Case Rep. 2012;6:195.View ArticlePubMedPubMed CentralGoogle Scholar
- Kaito K, Kobayashi M, Katayama T, Otsubo H, Ogasawara Y, Sekita T, et al. Prognostic factors of haemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol. 1997;59(4):247–53.View ArticlePubMedGoogle Scholar
- Brastianos PK, Swanson JW, Torbenson M, Sperati J, Karakousis PC. Tuberculosis associated haemophagocytic syndrome. Lancet Infect Dis. 2006;6(7):447–54.View ArticlePubMedGoogle Scholar
- Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial haemophagocytic lymphangiohistiocytosis. Acta Paediatr Scand. 1991;80(4):428–35.View ArticlePubMedGoogle Scholar
- Ishii E, Ohga S, Imashuku S, Kimura N, Ueda I, Morimoto A, et al. Review of haemophagocytic lymphangiohistiocytosis (HLH) in children with focus on Japanese experiences. Crit Rev Oncol Haematol. 2005;53(3):209–23.View ArticleGoogle Scholar
- Creput C, Galicier L, Buyse S, Azoulay E. Understanding organ dysfunction in haemophagocytic lymphangiohistiocytosis. Intensive Care Med. 2008;34:1177–87.View ArticlePubMedGoogle Scholar
- Tseng YT, Sheng WH, Lin BH, Lin CW, Wang JT, Chen YC, et al. Causes, clinical symptoms and outcomes of infectious diseases associated with haemophagocytic lymphangiohistiocytosis in Taiwanese adults. J Microbiol Immunol Infect. 2011;44(3):191–7.View ArticlePubMedGoogle Scholar
- Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis: The FHL Study Group of the Histiocyte Society. Semin Oncol. 1991;18(1):29–33.PubMedGoogle Scholar